Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2026; 32(45): 122523
Published online Dec 7, 2026. doi: 10.3748/wjg.122523
Published online Dec 7, 2026. doi: 10.3748/wjg.122523
Multi-omics analysis identifies COX6A2/SCF/c-Kit-mediated mitochondrial remodeling as a key mechanism of Tangwei’an decoction in diabetic gastroparesis
Yu-Xin Zhang, Bin Li, Department of Acupuncture and Moxibustion, Beijing Key Laboratory of Acupuncture Neuromodulation, Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China
Yu-Xin Zhang, Xin-Yi Fang, Yan-Jiao Zhang, Rui-Yang Yin, Jia-Xing Tian, Institute of Metabolic Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
Co-first authors: Yu-Xin Zhang and Xin-Yi Fang.
Co-corresponding authors: Bin Li and Jia-Xing Tian.
Author contributions: Zhang YX contributed to writing - original draft; Fang XY contributed to validation; Zhang YX and Fang XY contributed to visualization and made equal contributions as co-first authors; Zhang YJ contributed to formal analysis and data curation; Yin RY contributed to investigation and methodology; Li B and Tian JX contributed to writing - review & editing and made equal contributions as co-corresponding authors; Tian JX contributed to funding acquisition and formal analysis. All authors approved the final version to publish.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Supported by GAMIMD Special Fund, No. 2022LYJSZX12; CACMS Outstanding Young Scientific and Technological Talents Program, No. ZZ13-YQ-026; and CACM-PDP Dose-Effect Relationship Research Project, No. 202428-002.
Institutional animal care and use committee statement: All procedures were approved by the Institutional Animal Care and Use Committee of Beijing Pharmacokang Biotechnology Co., Ltd., No. GPT-BJAP20240328-1.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All mass spectrometry data from this study, including proteomics and metabolomics datasets, are publicly available in the OMIX database. The data can be accessed using accession number OMIX008366 for proteomics (https://ngdc.cncb.ac.cn/omix/release/OMIX008366) and OMIX008349 for metabolomics (https://ngdc.cncb.ac.cn/omix/release/OMIX008349).
Corresponding author: Jia-Xing Tian, Institute of Metabolic Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China. tina-yai@126.com
Received: April 22, 2026
Revised: June 25, 2026
Accepted: July 13, 2026
Published online: December 7, 2026
Processing time: 176 Days and 22.7 Hours
Revised: June 25, 2026
Accepted: July 13, 2026
Published online: December 7, 2026
Processing time: 176 Days and 22.7 Hours
Core Tip
Core Tip: Tangwei’an decoction (TWAD) is clinically used for diabetic gastroparesis (DGP), but its mechanism remains unclear. This study combined serum pharmacochemistry, integrated proteomics and metabolomics, and experimental validation to show that TWAD alleviates DGP by restoring mitochondrial dynamics. Oxidative phosphorylation was identified as the major pathway regulated by TWAD, with COX6A2 as a key target. TWAD also modulated the SCF/c-Kit axis, providing mechanistic support for its therapeutic potential in DGP.